Monetizing Focus: Tesaro Adds Runway By Out-licensing Niraparib In Prostate Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Janssen pays $40m up front with sizeable earn-outs for right to develop PARP inhibitor in prostate cancer, while Tesaro will continue with development of niraparib in ovarian, breast and lung cancer.